The study evaluates how omega-3 delivery architecture influences triglyceride outcomes and omega-3 incorporation in ...
Zacks Investment Research on MSN
NTLA stock up more than 6% as FDA lifts ATTRv-PN study clinical hold
Intellia Therapeutics NTLA announced that the FDA lifted the clinical hold on the investigational new drug application (IND) ...
Activation of immune blood biomarkers from interferon gamma pathway distinguished long-term survivors (>=2 years) ...
A cohort study finds the risk for acne in patients on JAK inhibitors for atopic dermatitis was about 2.5 times greater than ...
CANTANHEDE, PORTUGAL, NEW YORK CITY, USA AND DUBLIN, IRELAND, January 12, 2026 /EINPresswire.com/ -- • An early-phase ...
Adolescents and young adults aged 14 to 25 years with glomerular disease present with distinct clinical profiles compared ...
A new in vivo pharmacokinetic recall study involving 114 participants in the Estonian Biobank has provided the first clinical ...
The Phase 1 clinical study is expected to enroll approximately 24 healthy adult volunteers. The primary objectives of the study are to characterize the pharmacokinetic release profile of the nalmefene ...
Alphamab Oncology (Stock Code: 9966.HK) announced that the results from a phase III clinical study for the treatment of ...
"LUMEE”, "PROFUSA” and the PROFUSA logo are registered trademarks of Profusa Inc. in the United States, Canada, European Union, China, Japan, South Korea and Australia. For more information, visit ...
"ICVAX is built on the innovative PD-1-Enhanced DNA vaccine technology invented and developed locally at the HKU," said Professor Zhiwei CHEN. "This study will help optimize delivery of ICVAX, paving ...
New eTMF module integrates with Enlighten Clinical Solutions’ platform to support inspection-ready clinical trial ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results